Literature DB >> 8674896

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.

H Vlassara1, R Bucala.   

Abstract

Advanced glycosylation end products (AGEs) form principally from the rearrangement of early glycation products, i.e., Amadori products, which produce a class of stable moieties that possess distinctive chemical crosslinking and biological properties. It has been generally believed that proteins with half-lives of longer than a few weeks are most susceptible to advanced glycosylation and that the highest levels of AGEs occur on proteins that comprise the long-lived structural components of connective tissue matrix and basement membrane.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674896     DOI: 10.2337/diab.45.3.s65

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

1.  Estimating relative carbonyl levels in muscle microstructures by fluorescence imaging.

Authors:  Juan Feng; Marian Navratil; LaDora V Thompson; Edgar A Arriaga
Journal:  Anal Bioanal Chem       Date:  2008-06-12       Impact factor: 4.142

Review 2.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

3.  PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago.

Authors:  Steve Ian Smith
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

4.  Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets.

Authors:  Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-02       Impact factor: 4.799

Review 5.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

6.  Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis.

Authors:  J J Li; D Dickson; P R Hof; H Vlassara
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

7.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.

Authors:  David M Nathan; John Lachin; Patricia Cleary; Trevor Orchard; David J Brillon; Jye-Yu Backlund; Daniel H O'Leary; Saul Genuth
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

8.  Aging and atherosclerosis in human and nonhuman primates.

Authors:  W T Cefalu; J D Wagner
Journal:  Age (Omaha)       Date:  1997-01

9.  DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.

Authors:  Sho-Ichi Yamagishi; Kensei Taguchi; Kei Fukami
Journal:  Glycoconj J       Date:  2016-06-24       Impact factor: 2.916

10.  Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Authors:  Karly C Sourris; Anna Watson; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.